Cell News and Research

RSS

Threshold announces TH-302 Phase 1/2 clinical trial interim results

Threshold Pharmaceuticals, Inc. today announced interim results from an ongoing Phase 1/2 clinical trial in various solid tumors related to its hypoxia-activated prodrug, TH-302. The results were presented at the European Society for Medical Oncology (ESMO) Annual Meeting being held in Milan, Italy.

13 Oct 2010

Cellectis bioresearch establishes US subsidiary

Cellectis bioresearch, a specialist in genome customization and subsidiary of Cellectis, today announced that it has established a US subsidiary, Cellectis bioresearch Inc. Located at the Cambridge Innovation Center in Cambridge, Massachusetts, Cellectis bioresearch Inc. will be responsible for the US-wide promotion of Cellectis bioresearch products and services.

13 Oct 2010

Stem cell-enriched autologous fat treatment safe for breast reconstruction after cancer surgery

Since 2003, breast augmentation utilizing stem cells from autologous fat has been developed enabling silicon-free breast reconstruction following cancer surgery. Till now though, it was unclear whether this might reactivate the cancer again. However, University of Pittsburgh researchers led by Prof. Albert Donnenberg have now demonstrated that stem cell-enriched autologous fat is safe even in the presence of inactive tumor cells.

13 Oct 2010

Infection during pregnancy linked to increased risk for neurodevelopmental disorders in fetus

A pregnant woman's immune response to viral infections may induce subtle neurological changes in the unborn child that can lead to an increased risk for neurodevelopmental disorders including schizophrenia and autism. Research published in the online journal mBio- provides new insights into how this may happen and suggests potential strategies for reducing this risk.

13 Oct 2010

Boehringer Ingelheim awards milestone payment to Xencor

Xencor, Inc. announced today that the Company received a milestone payment from Boehringer Ingelheim. The payment was triggered by the regulatory submission for Phase 1 clinical trials of a novel monoclonal antibody that was optimized using one of Xencor's XmAb Fc (constant fragment) technology platforms under a technology license agreement entered in February 2007.

13 Oct 2010

CEL-SCI receives Taiwanese IRB approval for Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today it has received approval from the first Taiwanese Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.

13 Oct 2010

Immunomedics receives additional patent claims for antibody therapy

Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that additional claims for the patent family "Method and kit for imaging and treating organs and tissue," were issued as U.S. Patent No. 7,811,570.

13 Oct 2010

Scientists design synthetic molecule to protect liver cancer cells from toxic effects of chemotherapy

Scientists have found that a synthetic molecule they designed can block activation of a gene in liver cancer cells, halting a process that allows some of those cancer cells to survive chemotherapy.

13 Oct 2010

Researchers find gene association between Type 2 diabetes and Alzheimer's disease progression

Mount Sinai School of Medicine researchers have found that a gene associated with the onset of Type 2 diabetes also is found at lower-than-normal levels in people with Alzheimer's disease. The research, led by Giulio Maria Pasinetti, MD, PhD, The Saunder Family Professor in Neurology, and Professor of Psychiatry and Geriatrics and Adult Development at Mount Sinai School of Medicine, was published this month in Aging Cell.

13 Oct 2010

HSV1716 clinical trial for childhood cancer receives FDA grant

A clinical trial testing a genetically reprogrammed herpes simplex virus as treatment for deadly forms of childhood cancer has received a U.S. Food and Drug Administration grant to support the research.

13 Oct 2010

CSL to distribute Cerus' INTERCEPT Blood System in Australia, New Zealand

Cerus Corporation announced today that it has entered into an agreement with CSL Limited, Biotherapies division to distribute Cerus' INTERCEPT Blood System for platelets in Australia and New Zealand. The INTERCEPT Blood System is designed to provide increased protection from a broad range of transfusion-transmitted pathogens, including bacteria and emerging pathogens such as the dengue and chikungunya viruses.

13 Oct 2010

Cardiogenesis initiates enrollment in PHOENIX System Feasibility Study

Cardiogenesis Corporation, a leading developer of surgical products used in the treatment of diffuse coronary artery disease, reported the enrollment of the first two patients in its PHOENIX Feasibility Study. Dr. Guillermo Reyes at La Princesa Hospital, Madrid, Spain performed the procedures utilizing the company's proprietary PHOENIX System that combines the intramyocardial delivery of stem cells with transmyocardial revascularization (TMR).

13 Oct 2010

Scientists identify mutant protein in type 2 diabetes

University of Michigan scientists have identified events inside insulin-producing pancreatic cells that set the stage for a neonatal form of non-autoimmune type 1 diabetes, and may play a role in type 2 diabetes as well. The results point to a potential target for drugs to protect normally functioning proteins essential for producing insulin.

13 Oct 2010

Incept completes first U.S. human clinical trial of SMART Start Embryo Culture System

Incept BioSystems, Inc. a privately-held biomedical device company using patented, microfluidic technology developed at the University of Michigan, announced today the completion of the first U.S. human clinical trial of its proprietary, SMART Start Embryo Culture System, and the recent submission of a 510(k) application to the U.S. Food & Drug Administration.

13 Oct 2010

Exiqon introduces on-line microRNA qPCR assay design software

Exiqon A/S, a leading supplier of high-value gene expression analysis products, today announced the extension of the miRCURY LNA microRNA PCR product line with the launch of a novel bioinformatics software for the design of custom qPCR assays for microRNA quantification.

12 Oct 2010

Elsevier, AMP, ASIP to publish The Journal of Molecular Diagnostics

Elsevier, a world-leading publisher of scientific, technical and medical information products and services, is pleased to announce that as of January 2011 Elsevier will publish The Journal of Molecular Diagnostics (JMD) in partnership with the Association for Molecular Pathology (AMP) and the American Society for Investigative Pathology (ASIP).

12 Oct 2010

Elsevier, ASIP to publish The American Journal of Pathology

Elsevier, a world-leading publisher of scientific, technical and medical information products and services, is pleased to announce that as of January 2011 Elsevier will publish The American Journal of Pathology (AJP) in partnership with the American Society for Investigative Pathology (ASIP).

12 Oct 2010

First Edition: October 12, 2010

Today's early morning highlights from major news organizations look at a probe of a California hospital chain, the effect that the governors' races around the country will have on the federal health law and a review of prescription purchases that shows more Americans are foregoing their medicines.

12 Oct 2010

NCKU develops novel stem cell therapy for heart repair

Assistant Prof. Patrick C. H. Hsieh of Institute of Nanotechnology and Microsystems Engineering, College of Medicine, National Cheng Kung University (NCKU), Tainan, Taiwan, has led a research team of myocardial regeneration to conduct an experiment on pigs and has proved that by combining self-assembling peptide nanofiber hydrogel with autologous bone marrow stem cell, myocardial protection after acute myocardial infarction, vascular regeneration and heart functions can be improved.

12 Oct 2010

Teen Art Show shares teenagers' emotions in artistic fashion

With the help of the Child Life Program at St. Jude Children's Research Hospital, 22 new pieces of art were revealed from 19 talented adolescent patients during the Teen Art Show. The artwork is on display in a hospital hallway that was transformed permanently into the Teen Art Gallery.

12 Oct 2010